Diabetes Insipidus and SIADH: Water Balance Disorders in ICU

Quick Answer

Diabetes Insipidus (DI) and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) represent opposite ends of the water balance spectrum in ICU, both resulting from dysregulation of arginine vasopressin (AVP/ADH). These conditions are particularly common in neurocritical care settings. [1,2]

Diabetes Insipidus:

• Polyuria (greater than 3 L/day or greater than 200 mL/hr) with dilute urine (urine osmolality less than 300 mOsm/kg)
• Central DI: Loss of ADH production (TBI, neurosurgery, pituitary tumors, brain death)
• Nephrogenic DI: Renal resistance to ADH (lithium, hypercalcemia, hypokalemia)
• Management: DDAVP 1-2 mcg IV every 8-12 hours (central DI); free water replacement

SIADH:

• Hyponatremia (sodium less than 135 mmol/L) with concentrated urine (urine osmolality greater than 100 mOsm/kg) despite low serum osmolality
• Euvolemic state with inappropriately elevated ADH
• Causes: CNS disorders, pulmonary disease, malignancy, medications, pain
• Management: Fluid restriction (less than 1 L/day), salt tablets, urea, tolvaptan

Key Diagnostic Differentiation:

ICU Mortality: Dependent on underlying pathology; DI in brain death has 100% mortality without progression to organ donation. [3,4]

---

CICM Exam Focus

What Examiners Expect

Second Part Written (SAQ):

Common SAQ stems for water balance disorders:

• "A 42-year-old male is Day 3 post-transsphenoidal pituitary surgery. Observations: HR 110, BP 95/60, urine output 400 mL/hr for the last 4 hours. Na+ 152 mmol/L, serum osmolality 310 mOsm/kg, urine osmolality 85 mOsm/kg. Outline your diagnosis, investigations, and management."

• "A 65-year-old female with small cell lung cancer presents with confusion. Na+ 118 mmol/L, serum osmolality 248 mOsm/kg, urine osmolality 420 mOsm/kg, urine sodium 45 mmol/L. Describe the diagnostic criteria for SIADH and your management approach."

• "A patient with severe TBI develops polyuria (600 mL/hr) and sodium 158 mmol/L on Day 2. Discuss the pathophysiology and management, including the significance for prognosis."

Expected depth:

• Systematic diagnostic approach: Serum/urine osmolality, volume assessment, urine sodium
• Pathophysiology explanation: ADH synthesis, V2 receptor, aquaporin-2 channels
• Time-based management: Immediate (DDAVP, fluids) vs. ongoing (monitoring, correction rate)
• Complication awareness: Osmotic demyelination, brain edema, cardiovascular collapse
• Evidence-based interventions: European/Endocrine Society guidelines
• Neurosurgical context: Triple-phase response, brain death implications

Second Part Hot Case:

Typical presentations:

• Post-craniotomy patient with high urine output, hypernatremia, and hemodynamic instability
• Neurosurgical patient with hyponatremia - differentiate SIADH from cerebral salt wasting
• TBI patient with fluctuating sodium levels (triple-phase response)

Examiners assess:

• Systematic A-E examination approach
• Recognition of volume status (crucial for SIADH vs. CSW differentiation)
• Understanding of urine and serum osmolality relationship
• Clear one-minute summary synthesizing diagnosis
• Management prioritization including monitoring frequency
• Family communication regarding prognosis in brain death

Second Part Viva:

Expected discussion areas:

• ADH physiology: Synthesis in hypothalamic nuclei, storage in posterior pituitary, V2 receptor signaling
• Free water clearance calculation and interpretation
• DDAVP dosing regimens and monitoring parameters
• Tolvaptan mechanism and evidence (SALT trials, TIPS trial)
• Cerebral salt wasting vs. SIADH differentiation
• Brain death testing and DI management in potential organ donors
• Triple-phase response after pituitary surgery

Examiner expectations:

• Safe, consultant-level decision-making
• Evidence-based practice (cite European guidelines, Endocrine Society guidelines)
• Understanding of sodium correction rates and ODS prevention
• Resource stewardship (appropriate use of tolvaptan, monitoring frequency)
• Indigenous health awareness (access to chronic DI management in remote communities)

Common Mistakes

1. Confusing SIADH with cerebral salt wasting - Volume status is key: euvolemic (SIADH) vs. hypovolemic (CSW)
2. Over-correcting hyponatremia - Maximum 8-10 mmol/L/24h to prevent ODS; use DDAVP clamp if overcorrection occurs
3. Delaying DDAVP in central DI - Massive polyuria causes rapid hemodynamic deterioration
4. Using urine specific gravity instead of osmolality - Osmolality is more accurate
5. Not recognizing triple-phase response - DI (Day 1-3) → SIADH (Day 3-7) → Permanent DI (Day 7+)
6. Forgetting to replace ongoing losses - Free water deficit calculation is a snapshot; ongoing losses continue
7. Using tolvaptan in severe symptomatic hyponatremia - 3% saline is first-line for acute symptomatic cases
8. Neglecting potassium and magnesium - Hypokalemia and hypomagnesemia cause nephrogenic DI resistance

---

Key Points

Must-Know Facts

1. ADH Physiology: ADH (arginine vasopressin) is synthesized in supraoptic and paraventricular nuclei of the hypothalamus, transported via the hypothalamic-hypophyseal tract, and stored in the posterior pituitary. V2 receptors in the collecting duct mediate antidiuretic effect via aquaporin-2 channel insertion. [5,6]

2. Diabetes Insipidus Definition: Polyuria (greater than 3 L/24h or greater than 200 mL/hr) with dilute urine (osmolality less than 300 mOsm/kg) due to inadequate ADH action. Central DI involves ADH production failure; nephrogenic DI involves renal resistance to ADH. [7]

3. Central DI Causes in ICU: Traumatic brain injury (20-30%), transsphenoidal surgery (10-20%), pituitary tumors, infiltrative diseases, brain death (80-90%). The severity correlates with hypothalamic-pituitary axis injury. [8,9]

4. Nephrogenic DI Causes: Lithium (15-40% of long-term users), hypercalcemia, hypokalemia, tubulointerstitial disease, medications (amphotericin B, foscarnet, demeclocycline). [10,11]

5. SIADH Diagnostic Criteria (Bartter-Schwartz): Hyponatremia (less than 135 mmol/L), low serum osmolality (less than 280 mOsm/kg), inappropriately concentrated urine (greater than 100 mOsm/kg), elevated urine sodium (greater than 30 mmol/L), euvolemia, normal thyroid and adrenal function. [12,13]

6. Cerebral Salt Wasting Differentiation: Both have hyponatremia and elevated urine sodium, but CSW is hypovolemic with negative sodium balance. Treatment is saline replacement (not fluid restriction). [14,15]

7. Triple-Phase Response: After pituitary/hypothalamic injury - Phase 1 (DI, days 1-3): Impaired ADH release; Phase 2 (SIADH, days 3-7): Unregulated ADH release from dying neurons; Phase 3: Permanent DI (if greater than 80% neurohypophyseal axons destroyed). [16]

8. Sodium Correction Safety: For hyponatremia, correct less than 8-10 mmol/L/24h (less than 18 mmol/L/48h); for hypernatremia, correct less than 10 mmol/L/24h. Overcorrection causes osmotic demyelination (hyponatremia) or cerebral edema (hypernatremia). [17,18]

9. DDAVP Dosing: 1-4 mcg IV every 8-12 hours (or 10-20 mcg intranasal, 100-400 mcg oral). Monitor urine output and serum sodium every 4-6 hours initially. [19]

10. Brain Death and DI: Massive DI occurs in 80-90% of brain-dead patients due to destruction of hypothalamic-pituitary axis. Aggressive management is critical for organ donor optimization. [20,21]

Memory Aids

SIADH Causes - "CNS DRUG PAIN":

• CNS disorders (stroke, hemorrhage, infection, trauma)
• Neoplasms (especially small cell lung cancer)
• Surgery (post-operative)
• Drugs (SSRIs, carbamazepine, opioids, NSAIDs, cyclophosphamide)
• Respiratory (pneumonia, TB, positive pressure ventilation)
• Unknown/idiopathic
• Gross stress/pain/nausea
• Porphyria
• AIDS/HIV
• Infections (pulmonary)
• Nausea/pain (potent non-osmotic ADH stimuli)

DI Types - "CENTRAL stops making, NEPHRO stops responding":

• CENTRAL: Problem with production (brain/pituitary)
• NEPHROGENIC: Problem with response (kidney)

---

Definition and Epidemiology

Definition

Diabetes Insipidus (DI) is a syndrome characterized by the excretion of abnormally large volumes of dilute urine, resulting from either inadequate secretion of antidiuretic hormone (central/neurogenic DI) or impaired renal response to ADH (nephrogenic DI). The hallmark is polyuria (greater than 50 mL/kg/day or greater than 3 L/day in adults) with hypotonic urine (less than 300 mOsm/kg). [7,22]

Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is defined as hyponatremia resulting from continued ADH secretion or action despite conditions that normally suppress it, leading to impaired free water excretion. The 2014 European Clinical Practice Guidelines define SIADH using the Bartter-Schwartz criteria. [12,13]

Severity Classification - Diabetes Insipidus:

Severity Classification - Hyponatremia (SIADH):

Epidemiology

Diabetes Insipidus in ICU:

The incidence of DI varies by clinical context:

Traumatic Brain Injury: DI occurs in 2.9-51% of TBI patients depending on severity. A meta-analysis of 11 studies found DI in approximately 26% of moderate-to-severe TBI. Risk factors include GCS less than 8, basal skull fracture, and prolonged hypoxia. [8,23]

Neurosurgery: Post-operative DI occurs in 10-20% of transsphenoidal surgeries, 5-10% of craniotomies for parasellar tumors. Most cases are transient (70-80%), with permanent DI in 2-5%. [9,24]

Brain Death: DI develops in 80-90% of brain-dead patients due to destruction of the hypothalamic-pituitary axis. This is a critical consideration for organ donor management. [20,21]

Nephrogenic DI: Lithium causes nephrogenic DI in 15-40% of chronic users. The incidence is dose and duration-dependent. Other causes (hypercalcemia, hypokalemia) are common in ICU. [10,11]

SIADH in ICU:

SIADH is the most common cause of euvolemic hyponatremia in hospitalized patients:

Neurosurgical Patients: SIADH occurs in 30-40% of subarachnoid hemorrhage patients (peak days 7-10), 20-30% after pituitary surgery, and 10-20% after traumatic brain injury. [25,26]

Pulmonary Disease: Pneumonia, tuberculosis, and mechanical ventilation are associated with SIADH. Positive pressure ventilation reduces venous return, triggering non-osmotic ADH release. [27]

Malignancy: Small cell lung cancer causes SIADH in 10-15% of cases via ectopic ADH production. Other tumors (head/neck, GI, lymphoma) may also cause SIADH. [28]

Medications: SSRIs cause hyponatremia in 0.5-25% of patients, with highest risk in elderly females. Carbamazepine, oxcarbazepine, and cyclophosphamide are other common causes. [29]

Australian/NZ Data (ANZICS APD):

Hyponatremia (sodium less than 130 mmol/L) on ICU admission is associated with increased mortality (OR 1.4-1.8) across Australian and New Zealand ICUs. Indigenous Australians have higher rates of electrolyte disorders due to increased prevalence of chronic kidney disease, diabetes, and medication use. [30,31]

Indigenous Health Considerations:

Aboriginal and Torres Strait Islander peoples face unique challenges with water balance disorders:

• Higher rates of chronic kidney disease affecting fluid handling
• Increased lithium use for psychiatric conditions with less frequent monitoring
• Remote community access barriers for chronic DI management requiring regular DDAVP
• Limited access to specialist endocrinology follow-up

---

Applied Basic Sciences

ADH Physiology

Synthesis and Storage:

Arginine vasopressin (AVP/ADH) is a 9-amino acid peptide synthesized in magnocellular neurons of the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus. The hormone is packaged with neurophysin II into secretory granules that travel down axons through the hypothalamic-hypophyseal tract to the posterior pituitary (neurohypophysis), where approximately 10% of the total AVP is stored. [5,6,32]

The posterior pituitary contains approximately 0.1-1.0 mcg of AVP, sufficient for 5-10 days of normal secretion. This reserve explains why acute injury often causes transient DI, while permanent DI requires destruction of greater than 80-90% of AVP-producing neurons. [16]

Regulation of ADH Release:

Osmotic Triggers (Primary):

• Osmoreceptors in the anterior hypothalamus detect plasma osmolality changes as small as 1-2%
• Threshold for ADH release: Plasma osmolality approximately 280-285 mOsm/kg
• Linear relationship between osmolality and ADH above threshold
• Maximal antidiuresis occurs at plasma osmolality greater than 295 mOsm/kg [33]

Non-Osmotic Triggers:

• Hypovolemia: Volume depletion (greater than 5-10% blood volume) activates baroreceptors in carotid sinus, aortic arch, and left atrium
• Hypotension: Triggers ADH release via arterial baroreceptors
• Pain and nausea: Potent non-osmotic stimuli (explains post-operative SIADH)
• Stress: Surgery, trauma, positive pressure ventilation
• Medications: Opioids, SSRIs, carbamazepine, cyclophosphamide [27,34]

Non-osmotic stimuli can override osmotic regulation, explaining SIADH despite low serum osmolality.

ADH Receptors:

V2 Receptor Signaling and Aquaporin-2:

1. ADH binds V2 receptor on basolateral membrane of collecting duct principal cells
2. G-protein (Gs) activates adenylyl cyclase, increasing cAMP
3. cAMP activates protein kinase A (PKA)
4. PKA phosphorylates aquaporin-2 (AQP2) in cytoplasmic vesicles
5. Phosphorylated AQP2 translocates and inserts into apical membrane
6. Water moves through AQP2 (apical) and AQP3/4 (basolateral) into medullary interstitium
7. Result: Concentrated urine, water conservation [35,36]

Long-term ADH exposure also increases AQP2 gene transcription.

Free Water Clearance:

Free water clearance (CH2O) quantifies the kidney's ability to excrete or retain free water:

CH2O = V - Cosm

Where:

• V = Urine volume (mL/min)
• Cosm = Osmolar clearance = (Uosm x V) / Posm

Interpretation:

• Positive CH2O (free water excretion): Dilute urine relative to plasma - seen in DI
• Negative CH2O (free water retention): Concentrated urine - seen in SIADH
• Electrolyte-free water clearance accounts only for electrolytes: CH2O(e) = V x [1 - (UNa + UK) / PNa]

This concept is crucial for understanding why fluid type matters in management. [37]

Pathophysiology of Diabetes Insipidus

Central DI Pathophysiology:

Central DI results from insufficient ADH secretion due to damage to the hypothalamic-pituitary axis:

Anatomical Considerations:

• Damage above the median eminence (hypothalamic nuclei) → Permanent DI (axons cannot regenerate)
• Damage below median eminence (pituitary stalk, posterior pituitary) → May be transient (proximal axons can regenerate)
• Isolated posterior pituitary damage → Usually transient DI (hormone stored in nerve terminals can be released) [38]

Common Causes in ICU:

1. Traumatic Brain Injury: Direct damage to hypothalamus or pituitary stalk from acceleration-deceleration forces. Risk correlates with GCS, basal skull fracture, prolonged hypoxia. [8,23]

2. Neurosurgery: Transsphenoidal surgery (10-20%), craniopharyngioma resection (50-90%), suprasellar tumors. Operative technique and tumor size are risk factors. [9,24]

3. Brain Death: Loss of hypothalamic function causes loss of ADH production, resulting in massive DI in 80-90% of brain-dead patients. [20,21]

4. Pituitary Tumors: Large macroadenomas (greater than 10 mm) or apoplexy can compress or destroy the posterior pituitary or stalk.

5. Infiltrative Diseases: Sarcoidosis, histiocytosis, metastases (breast, lung), lymphoma.

6. Infections: Encephalitis, meningitis (especially tuberculosis), CMV in immunocompromised.

7. Vascular: Pituitary apoplexy, Sheehan syndrome (postpartum), aneurysms.

Nephrogenic DI Pathophysiology:

Nephrogenic DI results from renal resistance to ADH despite normal or elevated circulating ADH levels:

Mechanisms of ADH Resistance:

1. Lithium (most common acquired cause):

   • Enters collecting duct cells via ENaC
   • Inhibits adenylyl cyclase, reducing cAMP generation
   • Decreases AQP2 expression (50-80% reduction)
   • Causes tubular interstitial nephritis with chronic use
   • Partially reversible if lithium discontinued early [10,39]

2. Hypercalcemia:

   • Calcium activates calcium-sensing receptor (CaSR) in collecting duct
   • CaSR activation reduces cAMP and AQP2 expression
   • Also causes direct tubulointerstitial damage
   • Usually reversible with calcium correction [40]

3. Hypokalemia:

   • Potassium depletion reduces AQP2 expression
   • Impairs medullary concentration gradient
   • Usually reversible with potassium replacement [41]

4. Medications: Amphotericin B (pore formation in collecting duct membranes), foscarnet, demeclocycline (used therapeutically in SIADH), ifosfamide.

5. Intrinsic Renal Disease: Chronic kidney disease, post-obstructive uropathy, sickle cell disease, polycystic kidney disease, medullary cystic disease.

Pathophysiology of SIADH

Mechanism of Inappropriate ADH Secretion:

In SIADH, ADH secretion or action continues despite:

• Low serum osmolality (normally suppresses ADH at less than 280 mOsm/kg)
• Euvolemia or hypervolemia (normally suppresses non-osmotic ADH release)

Categories of SIADH (Robertson Classification):

Physiological Consequences:

1. Water Retention: Inappropriate AQP2 insertion leads to water reabsorption despite low osmolality
2. Volume Expansion: Mild (5-10%) expansion of ECF
3. Natriuresis: Volume expansion activates ANP and suppresses aldosterone, causing sodium excretion
4. Hyponatremia: Dilutional effect plus sodium loss
5. Euvolemia Appearance: Natriuresis prevents clinically evident edema despite positive water balance [42]

CNS Effects of Hyponatremia:

The brain adapts to hyponatremia by extruding osmolytes:

• Acute (less than 48 hours): No adaptation → severe cerebral edema risk
• Chronic (greater than 48 hours): Brain extrudes osmolytes (organic solutes) → cells shrink toward normal → less symptomatic

Osmotic Demyelination Syndrome (ODS):

Rapid correction of chronic hyponatremia causes ODS (previously called central pontine myelinolysis):

• Brain cells cannot rapidly regain osmolytes
• Rapid osmolality increase causes cell shrinkage and demyelination
• Risk factors: Alcoholism, malnutrition, hypokalemia, chronic hyponatremia
• Presents 2-6 days after overcorrection with dysarthria, dysphagia, quadriparesis
• Prevention: Correct less than 8-10 mmol/L/24h (less than 6 mmol/L in high-risk patients) [17,18,43]

Pharmacology

Desmopressin (DDAVP):

• Class: Synthetic vasopressin analogue (1-deamino-8-D-arginine vasopressin)
• Mechanism: Selective V2 receptor agonist (1,000-fold selectivity over V1a); increases AQP2 insertion in collecting duct, enhancing water reabsorption
• ICU Indication: Central DI, mild hemophilia A/vWD (releases factor VIII and vWF), diagnosis of DI (desmopressin challenge)
• Dosing:
  • "IV/SC: 1-4 mcg every 8-12 hours"
  • "Intranasal: 10-40 mcg (0.1-0.4 mL) every 12-24 hours"
  • "Oral: 100-400 mcg every 8-12 hours (10% bioavailability)"
• Monitoring: Urine output (target less than 200 mL/hr), serum sodium (every 4-6 hours initially), serum osmolality
• Adverse Effects: Hyponatremia (especially with excessive free water intake), headache, flushing, nausea
• PBS/TGA: PBS listed for DI; available in all formulations [19,44]

Tolvaptan:

• Class: Vasopressin V2 receptor antagonist (vaptan)
• Mechanism: Blocks V2 receptor, preventing ADH-mediated water reabsorption; causes aquaresis (free water excretion without electrolyte loss)
• ICU Indication: SIADH with persistent hyponatremia despite fluid restriction; euvolemic/hypervolemic hyponatremia
• Dosing: 15 mg oral daily initially; can increase to 30-60 mg/day. Maximum duration 30 days due to hepatotoxicity risk
• Monitoring: Serum sodium (every 6 hours for first 24-48 hours), LFTs (weekly during treatment), fluid intake (patients experience intense thirst)
• Adverse Effects: Overcorrection of sodium (limit rise to less than 10 mmol/L/24h), hepatotoxicity, thirst, dry mouth
• Contraindications: Hypovolemic hyponatremia, inability to sense/respond to thirst, hepatic impairment, pregnancy
• Evidence: SALT-1/SALT-2 trials demonstrated efficacy in SIADH; TIPS trial showed benefit in ICU patients
• PBS/TGA: TGA approved but not PBS-listed; significant cost implications [45,46,47]

3% Hypertonic Saline:

• Class: Hypertonic crystalloid (513 mmol/L sodium)
• Mechanism: Raises serum sodium rapidly by shifting water from intracellular to extracellular compartment
• ICU Indication: Severe symptomatic hyponatremia (seizures, coma), raised ICP
• Dosing: 100 mL bolus over 10 minutes; raises sodium by approximately 2 mmol/L; repeat up to 3 times for severe symptoms. Alternatively, infusion at 0.5-2 mL/kg/hr
• Monitoring: Serum sodium every 2-4 hours during correction
• Adverse Effects: Volume overload, overcorrection, central venous access recommended (hyperosmolar)
• Target: Increase sodium by 4-6 mmol/L in first 1-2 hours for symptomatic hyponatremia; then slow to less than 8-10 mmol/L/24h [48]

Demeclocycline:

• Class: Tetracycline antibiotic
• Mechanism: Induces nephrogenic DI by inhibiting ADH action on collecting duct (mechanism not fully understood; possibly inhibits cAMP generation)
• ICU Indication: Chronic SIADH when fluid restriction fails (less used now due to vaptans)
• Dosing: 300-600 mg orally twice daily
• Monitoring: Renal function (nephrotoxic), serum sodium
• Adverse Effects: Nephrotoxicity, photosensitivity, GI upset, azotemia
• Limitations: Slow onset (3-6 days), unpredictable response, nephrotoxicity limits ICU use [49]

Urea:

• Class: Osmotic agent
• Mechanism: Increases osmolar load, promoting free water excretion; also helps prevent overcorrection of sodium
• ICU Indication: Chronic SIADH, prevention of osmotic demyelination during hyponatremia correction
• Dosing: 15-60 g/day orally or via NG tube (mixed with orange juice to mask bitter taste)
• Adverse Effects: GI intolerance, unpalatable taste
• Advantages: Cheap, effective, safer than tolvaptan for gradual sodium elevation [50]

---

Clinical Presentation

ICU Admission Scenarios

Scenario 1: Post-Transsphenoidal Surgery with Central DI

• History: 45-year-old male, Day 2 post-transsphenoidal resection of pituitary macroadenoma. Suddenly producing large volumes of clear urine (600 mL over last hour).
• Examination: Tachycardic (HR 105), hypotensive (BP 95/55), dry mucous membranes, postural hypotension, decreased skin turgor
• Investigations: Na+ 155 mmol/L, serum osmolality 315 mOsm/kg, urine osmolality 90 mOsm/kg, urine specific gravity 1.002
• Severity: Severe - requires immediate DDAVP and fluid resuscitation

Scenario 2: SAH with SIADH vs. Cerebral Salt Wasting

• History: 58-year-old female, Day 7 post-subarachnoid hemorrhage (Fisher Grade 3, Hunt and Hess Grade 3). Becoming progressively confused.
• Examination: Euvolemic (normal JVP, no edema, normal skin turgor), GCS 13 (down from 15), afebrile
• Investigations: Na+ 124 mmol/L, serum osmolality 258 mOsm/kg, urine osmolality 550 mOsm/kg, urine sodium 65 mmol/L
• Differential: SIADH (if euvolemic) vs. CSW (if hypovolemic) - critical differentiation
• Severity: Moderate-severe - requires careful diagnosis and management

Scenario 3: Severe TBI with Triple-Phase Response

• History: 28-year-old male, severe TBI (GCS 5 at scene), Day 5 post-admission. Initially had massive polyuria (Days 1-3), then stabilized, now developing oliguria.
• Examination: Intubated, sedated, ICP monitor in situ (ICP 18 mmHg), stable hemodynamics on noradrenaline
• Investigations: Day 5: Na+ 128 mmol/L (was 152 on Day 2), serum osmolality 268 mOsm/kg, urine osmolality 480 mOsm/kg
• Interpretation: Classic triple-phase response - now in Phase 2 (SIADH/inappropriate ADH release from dying neurons)
• Severity: Moderate - requires fluid restriction and close monitoring

Scenario 4: Brain Death Evaluation with Massive DI

• History: 35-year-old female, Day 3 post-cardiac arrest with refractory VF. Clinical examination concerning for brain death. Urine output 800 mL/hr for last 3 hours.
• Examination: No brainstem reflexes, off sedation greater than 24 hours, pupils fixed and dilated
• Investigations: Na+ 168 mmol/L, serum osmolality 340 mOsm/kg, urine osmolality 60 mOsm/kg, hemodynamically unstable despite vasopressors
• Interpretation: Massive DI consistent with loss of hypothalamic function; supports clinical suspicion of brain death
• Priority: Organ donor optimization if brain death confirmed

Symptoms and Signs

Diabetes Insipidus:

History:

• Chief complaint: Excessive thirst (polydipsia), excessive urination (polyuria)
• Polyuria: Greater than 3 L/day, often greater than 10 L/day in severe cases
• Nocturia: Multiple awakenings to urinate
• Preference for cold water (characteristic of DI)
• Fatigue, confusion (if hypernatremia develops)
• In ICU: Often first noted by nursing staff as massive urine output

Examination:

• General: May appear dehydrated if access to water is impaired

• Vital signs: Tachycardia, hypotension (if hypovolemic)

• A - Airway: Usually patent (unless neurological deterioration from hypernatremia)

• B - Breathing: Generally normal unless massive volume depletion

• C - Circulation:

  • Tachycardia (compensatory)
  • Hypotension if severe dehydration
  • Weak peripheral pulses
  • Prolonged capillary refill
  • Postural hypotension

• D - Disability:

  • GCS may be reduced if sodium greater than 160 mmol/L
  • Confusion, lethargy, coma
  • Hyperreflexia, muscle twitching
  • Seizures (rare, usually with rapid sodium changes)

• E - Exposure:

  • Dry mucous membranes
  • Decreased skin turgor
  • Sunken eyes
  • Large volumes of dilute urine in catheter bag

SIADH:

History:

• Chief complaint: Nausea, headache, confusion (symptoms of hyponatremia)
• Anorexia, malaise
• Muscle cramps
• Falls (common presentation in elderly)
• May be asymptomatic if chronic and mild (sodium greater than 125 mmol/L)

Examination:

• General: May appear well despite significant hyponatremia (chronic adaptation)

• Vital signs: Usually normal (euvolemic state)

• A - Airway: Usually patent unless severe encephalopathy

• B - Breathing: Cheyne-Stokes respiration if severe hyponatremia with brainstem compromise

• C - Circulation:

  • Normal blood pressure
  • Normal JVP
  • No peripheral edema (distinguishes from hypervolemic hyponatremia)
  • Normal skin turgor

• D - Disability:

  • GCS variable depending on severity and acuity
  • Confusion (sodium 125-130 mmol/L)
  • Obtundation (sodium 115-125 mmol/L)
  • Seizures, coma (sodium less than 115 mmol/L)
  • Deep tendon reflexes may be decreased

• E - Exposure:

  • No signs of volume depletion
  • No edema
  • Low or normal urine output

Severity Scoring

Diabetes Insipidus Severity:

No validated scoring system; severity assessed by:

• Urine output: Mild (3-5 L/day), Moderate (5-10 L/day), Severe (greater than 10 L/day)
• Serum sodium: Mild (145-150 mmol/L), Moderate (150-160 mmol/L), Severe (greater than 160 mmol/L)
• Response to desmopressin: Complete vs. partial vs. none (distinguishes central from nephrogenic)

Hyponatremia Severity (European Guidelines 2014):

Symptom Classification:

• Moderately symptomatic: Nausea, confusion, headache
• Severely symptomatic: Vomiting, cardiorespiratory distress, abnormal somnolence, seizures, GCS less than 8

Differential Diagnosis

Polyuria Differential (DI vs. Other Causes):

1. Primary Polydipsia (Psychogenic): Excessive water intake; low serum sodium, dilute urine, responds to water restriction; no response to DDAVP
2. Osmotic Diuresis: Hyperglycemia, mannitol, urea; high urine osmolality (greater than 300 mOsm/kg), high osmolar gap
3. Post-Obstructive Diuresis: After relief of urinary obstruction; usually transient
4. Chronic Kidney Disease (Polyuric phase): Impaired concentrating ability; elevated creatinine
5. Diuretic use: Check medication list

Distinguishing Central from Nephrogenic DI:

Hyponatremia Differential:

1. SIADH: Euvolemic, urine osmolality greater than 100, urine Na greater than 30
2. Cerebral Salt Wasting: Hypovolemic, negative sodium balance, high urine output
3. Adrenal Insufficiency: Check cortisol, low BP, hyperpigmentation, may have hyperkalemia
4. Hypothyroidism: Check TSH, slow relaxing reflexes
5. Heart Failure: Hypervolemic, elevated JVP, edema
6. Cirrhosis: Hypervolemic, ascites, jaundice
7. Diuretics: Medication history
8. Psychogenic Polydipsia: Dilute urine (less than 100 mOsm/kg), low-normal urine sodium

SIADH vs. Cerebral Salt Wasting:

This differentiation is critical - treating CSW with fluid restriction is harmful. [14,15]

---

Investigations

Laboratory Investigations

Bedside Tests:

Arterial Blood Gas:

• pH: Usually normal unless concurrent metabolic disturbance
• PaCO2: Normal
• Na+: Point-of-care sodium for rapid assessment
• Glucose: Rule out osmotic diuresis (hyperglycemia)
• Lactate: May be elevated in DI with hemodynamic compromise

Blood Tests:

Essential Panel for Water Balance Disorders:

Additional Tests:

• Cortisol: Random or early morning (rule out adrenal insufficiency as cause of hyponatremia)
• TSH/fT4: Rule out hypothyroidism (must be excluded before diagnosing SIADH)
• Glucose: Correct sodium for hyperglycemia: Corrected Na = Measured Na + 0.3 x [(glucose - 5.5)/5.5]
• Lipids/Proteins: Pseudohyponatremia with massive hyperlipidemia or hyperproteinemia (if using indirect ISE method)
• Potassium, Magnesium: Hypokalemia causes nephrogenic DI; hypomagnesemia must be corrected
• Calcium: Hypercalcemia causes nephrogenic DI

Water Deprivation Test (if diagnosis unclear):

Not typically performed in ICU (patients often cannot tolerate fluid restriction), but in stable patients:

1. Withhold fluids until 3% body weight lost or urine osmolality plateaus
2. Measure serum and urine osmolality
3. Administer desmopressin 2 mcg IV
4. Repeat urine osmolality at 1 and 2 hours

Interpretation:

• Normal: Urine osmolality greater than 600 mOsm/kg without DDAVP
• Central DI: Urine remains dilute, then concentrates greater than 50% post-DDAVP
• Nephrogenic DI: Urine remains dilute despite DDAVP

Desmopressin Challenge Test (ICU-appropriate):

For suspected DI:

1. Give DDAVP 2 mcg IV
2. Monitor urine output and osmolality over 4-8 hours
3. Measure serum sodium at baseline and 4-6 hours

Response:

• Central DI: Urine output decreases, osmolality increases greater than 50%
• Nephrogenic DI: Minimal response (less than 50% increase in urine osmolality)
• Primary polydipsia: Variable response (may show some concentration) [51]

Imaging

MRI Brain (Pituitary Protocol):

Indicated for suspected central DI:

Normal Posterior Pituitary: T1-weighted images show high signal ("bright spot") representing stored neurohypophyseal hormones

Central DI Findings:

• Loss of posterior pituitary bright spot (90% sensitivity for central DI)
• Pituitary stalk thickening or deviation
• Hypothalamic or pituitary masses
• Evidence of infiltrative disease

CT Brain:

• TBI patients: Assess for hemorrhage, edema, midline shift
• Neurosurgical patients: Post-operative changes, hemorrhage
• SAH patients: Fisher grade, hydrocephalus

Physiological Monitoring

Continuous Monitoring in DI:

• Hourly urine output: Target less than 200 mL/hr after treatment
• Continuous ECG: Hypernatremia can cause arrhythmias
• Arterial line: If hemodynamically unstable
• Central venous access: For volume resuscitation and DDAVP administration

Monitoring Frequency for Hyponatremia Treatment:

Fluid Balance:

• Strict input/output charting
• Daily weights (if possible)
• Cumulative fluid balance calculation

---

ICU Management

Initial Resuscitation - Diabetes Insipidus

A - Airway:

• Usually patent unless severe hypernatremia causes decreased consciousness
• Intubation for GCS less than 8 or airway compromise

B - Breathing:

• Supplemental oxygen if respiratory compromise from weakness
• Mechanical ventilation if intubated for neurological protection

C - Circulation:

Fluid Resuscitation for DI:

1. Assess volume status: HR, BP, CVP, urine output, skin turgor

2. Calculate free water deficit:

   Free Water Deficit (L) = TBW x [(Current Na/140) - 1]

   Where TBW = 0.6 x weight (males) or 0.5 x weight (females)

   Example: 70 kg male with Na+ 160 mmol/L:

   • TBW = 0.6 x 70 = 42 L
   • Free Water Deficit = 42 x [(160/140) - 1] = 42 x 0.143 = 6 L

3. Choose appropriate fluid:

   • If hypovolemic with hypotension: Initial bolus of 0.9% saline (isotonic) to restore perfusion
   • Once euvolemic: Switch to hypotonic fluid (0.45% saline or 5% dextrose)
   • Free water (5% dextrose) for pure water replacement

4. Rate of correction:

   • Target correction: Less than 10 mmol/L per 24 hours
   • Avoid more than 0.5-1 mmol/L per hour
   • Replace deficit over 48-72 hours

   Infusion Rate = (Free Water Deficit / Correction Time) + Ongoing Losses

5. Replace ongoing losses:

   • Match urine output with appropriate replacement until DDAVP takes effect
   • For massive polyuria (greater than 500 mL/hr): May need matched replacement until controlled

Vasopressors:

• Use if hypotensive despite fluid resuscitation
• Noradrenaline first-line (standard ICU practice)
• Vasopressin (0.01-0.04 units/min) can provide both V1 (vasopressor) and V2 (antidiuretic) effects in brain death/severe central DI [52]

D - Disability:

• Neurological assessment every 4 hours
• Treat underlying cause (e.g., neurosurgical intervention if needed)
• Seizure precautions if sodium greater than 160 mmol/L

E - Everything Else:

• Temperature: Maintain normothermia
• Glucose control: Target 6-10 mmol/L
• Electrolytes: Check and replace potassium, magnesium (both affect renal concentrating ability)

Definitive Management - Diabetes Insipidus

Central DI:

DDAVP (Desmopressin):

DDAVP Initiation Protocol:

1. Give DDAVP 1-2 mcg IV
2. Monitor urine output hourly
3. Allow serum sodium to fall by 0.5-1 mmol/L per hour (max 10 mmol/L/24h)
4. Repeat DDAVP when urine output rises greater than 200 mL/hr or sodium starts rising
5. Titrate dose to maintain normal urine output and stable sodium

Caution: Do not give DDAVP and large volumes of free water simultaneously - risk of overcorrection and water intoxication [19,44]

Nephrogenic DI:

Management is more challenging as DDAVP is ineffective:

1. Remove causative agent if possible (e.g., discontinue lithium)
2. Thiazide diuretics: Paradoxically reduce urine output by 30-50%
   • Mechanism: Induce mild volume depletion → enhanced proximal sodium and water reabsorption → less delivery to collecting duct
   • Dose: Hydrochlorothiazide 25-50 mg daily or chlorthalidone 25 mg daily
3. Low sodium diet: Reduces obligatory water excretion
4. NSAIDs: Indomethacin 50 mg TDS reduces urine output by inhibiting prostaglandin-mediated antagonism of ADH (use with caution in ICU due to renal effects)
5. Amiloride: Specifically useful for lithium-induced NDI; blocks lithium entry via ENaC
   • Dose: 5-10 mg daily
6. Adequate free water replacement: Primary management [53,54]

Initial Resuscitation - SIADH

A - Airway:

• Protect airway if GCS less than 8 or seizures
• Intubation may be required for severe symptomatic hyponatremia

B - Breathing:

• Standard care; ventilate if intubated

C - Circulation:

Severe Symptomatic Hyponatremia (Seizures, Coma):

3% Hypertonic Saline Protocol:

1. Immediate bolus: 100 mL 3% saline over 10 minutes (raises Na+ by approximately 2 mmol/L)
2. Reassess: Check symptoms, may repeat up to 3 times if ongoing severe symptoms
3. Target: Raise sodium by 4-6 mmol/L in first 1-2 hours
4. Check sodium: After bolus(es), then every 2-4 hours
5. 24-hour limit: Maximum 8-10 mmol/L correction in first 24 hours

Moderate Symptomatic Hyponatremia:

• 3% saline infusion at 0.5-2 mL/kg/hr
• Aim for 1-2 mmol/L/hr rise initially, then slow
• Frequent sodium monitoring (every 2-4 hours)

Mild/Asymptomatic Hyponatremia:

• Fluid restriction (less than 1000 mL/day or less than 500 mL less than urine output)
• Identify and treat underlying cause
• Do not correct rapidly [17,48]

D - Disability:

• Neurological monitoring every 2-4 hours
• Seizure management: Sodium correction is definitive treatment; benzodiazepines for active seizures
• GCS assessment

Definitive Management - SIADH

Step 1: Fluid Restriction

• First-line treatment for SIADH
• Restrict to less than 1000 mL/day (or 500 mL less than 24-hour urine output)
• Includes all oral and IV fluids

Step 2: Salt Tablets

• If fluid restriction insufficient
• Sodium chloride 1-3 g orally 2-3 times daily
• Increases obligatory water excretion

Step 3: Loop Diuretics

• Furosemide 20-40 mg with salt tablets
• Increases free water excretion while salt replaces sodium losses
• Monitor potassium

Step 4: Urea

• 15-60 g/day orally or via NG tube
• Osmotic diuresis increases free water excretion
• Safe, effective, cheap
• Mix with orange juice to mask bitter taste
• Particularly useful in neurosurgical patients [50]

Step 5: Tolvaptan

• V2 receptor antagonist
• Start 15 mg oral once daily
• Can increase to 30-60 mg/day
• Monitor sodium every 6 hours for first 24-48 hours
• Maximum 30 days use (hepatotoxicity risk)
• Allow free access to water (thirst sensation preserved)
• Contraindicated: Hypovolemia, liver disease, inability to sense thirst
• Evidence: SALT-1/SALT-2 trials showed efficacy; TIPS trial in ICU setting [45,46,47]

Step 6: Demeclocycline

• 300-600 mg orally twice daily
• Induces nephrogenic DI
• Slow onset (3-6 days)
• Nephrotoxic - avoid in renal impairment
• Less used now due to vaptans [49]

DDAVP Clamp for Overcorrection

If sodium rises too quickly (greater than 8-10 mmol/L/24h):

DDAVP Clamp Protocol:

1. Give DDAVP 2 mcg IV
2. Infuse 5% dextrose (D5W) to replace free water
3. Target: Lower sodium back toward safe correction rate
4. Continue DDAVP every 6-8 hours for 24-48 hours
5. Once sodium stable, gradually liberalize fluids

This creates a state of "controlled SIADH" preventing further sodium rise [55]

Special Situations

Post-Pituitary Surgery (Triple-Phase Response):

Management Approach:

• Monitor sodium and urine output every 4-6 hours
• Recognize phase transitions
• Avoid overcorrection in any direction
• Some patients do not complete all phases [16]

Brain Death and DI:

Organ Donor Optimization:

DI in brain death causes hemodynamic instability via:

• Massive volume loss (often greater than 500 mL/hr urine output)
• Electrolyte disturbances (hypernatremia, hypokalemia)
• Cardiovascular collapse

Management Protocol:

1. Volume replacement:

   • Initial: Balanced crystalloid to restore intravascular volume
   • Ongoing: 5% dextrose or 0.45% saline to replace free water losses

2. DDAVP:

   • Give DDAVP 2-4 mcg IV bolus
   • Then infusion or repeated boluses to maintain urine output less than 200 mL/hr

3. Vasopressin infusion:

   • Low-dose vasopressin 0.01-0.04 units/min
   • Provides both V1 (vasopressor) and V2 (antidiuretic) effects
   • May reduce noradrenaline requirements

4. Target hemodynamics:

   • MAP greater than 65 mmHg
   • CVP 6-10 mmHg
   • Urine output 1-3 mL/kg/hr (not less than 0.5 mL/kg/hr)

5. Electrolyte targets:

   • Sodium 135-155 mmol/L (mild hypernatremia acceptable)
   • Potassium 3.5-5.0 mmol/L (aggressive replacement often needed)
   • Correct metabolic acidosis

6. Hormone replacement (if available protocol):

   • T4 20 mcg IV bolus then 10 mcg/hr
   • Methylprednisolone 15 mg/kg
   • Vasopressin as above [20,21,52]

Cerebral Salt Wasting:

Key differentiation from SIADH is hypovolemia:

Management:

1. Volume replacement with 0.9% saline: First priority
2. Hypertonic saline 3%: If symptomatic or severe hyponatremia
3. Salt tablets: Oral supplementation
4. Fludrocortisone: 0.1-0.2 mg daily (mineralocorticoid; increases sodium retention)
5. Avoid fluid restriction: Worsens hypovolemia [14,15]

Australian-Specific Protocols

ANZICS-CORE Recommendations:

• Electrolyte monitoring every 4-6 hours in acute dysnatremia
• Target sodium correction less than 10 mmol/L/24 hours
• DDAVP first-line for central DI
• Hypertonic saline for severe symptomatic hyponatremia with neurological symptoms

Therapeutic Guidelines Australia:

• DDAVP available via PBS for DI
• Tolvaptan not PBS-listed (significant cost implications; hospital pharmacy approval often required)
• 3% saline via central access preferred (peripheral acceptable for small volumes with monitoring)

Indigenous Health Considerations:

• Remote communities: DDAVP storage (refrigerated intranasal/IV; oral formulation more stable)
• Limited pathology access: Urine specific gravity can be used if osmolality unavailable
• Telehealth consultation for complex cases
• Involve Aboriginal Health Workers and community for chronic DI management education
• Consider social determinants affecting medication adherence

---

Monitoring and Complications

ICU-Specific Monitoring

Diabetes Insipidus Monitoring:

SIADH/Hyponatremia Monitoring:

Signs of Overcorrection (Watch for 2-6 Days Post-Treatment):

• Dysarthria (slurred speech)
• Dysphagia
• Facial weakness
• Quadriparesis
• Altered consciousness
• Locked-in syndrome

MRI may be normal initially; repeat if ODS suspected [43]

Complications

Diabetes Insipidus Complications:

Hypernatremia-Related:

Volume-Related:

Treatment-Related:

SIADH/Hyponatremia Complications:

Hyponatremia-Related:

Treatment-Related:

Osmotic Demyelination Syndrome (ODS):

Previously called central pontine myelinolysis (though extrapontine structures also affected):

Risk Factors:

• Chronic hyponatremia (greater than 48 hours)
• Alcoholism
• Malnutrition
• Hypokalemia
• Liver disease
• Transplantation

Prevention:

• Limit correction to less than 8-10 mmol/L in first 24 hours
• In high-risk patients: Less than 6 mmol/L/24 hours
• Use DDAVP clamp if overcorrection occurs

Presentation (2-6 days after overcorrection):

• Dysarthria, dysphagia
• Quadriparesis (spastic)
• Pseudobulbar affect
• Locked-in syndrome (severe cases)
• Altered consciousness

Diagnosis:

• MRI: T2/FLAIR hyperintensity in pons (classic "trident" or "bat wing" appearance)
• May be delayed 2-4 weeks; initial MRI may be normal

Treatment:

• Supportive care
• Some advocate re-lowering sodium with DDAVP + D5W (controversial)
• Prognosis: 25-50% mortality; survivors may have permanent deficits [17,18,43]

---

Prognosis and Outcome Measures

Mortality

Diabetes Insipidus:

• Transient central DI (post-surgical): Minimal additional mortality; usually resolves
• Permanent central DI: Prognosis depends on underlying cause (e.g., pituitary tumor prognosis)
• Brain death with DI: 100% mortality (definition of death) unless organ donation proceeds
• Nephrogenic DI: Prognosis depends on cause; lithium-induced partially reversible; mortality low with treatment

SIADH/Hyponatremia:

Osmotic Demyelination Syndrome:

• Mortality: 25-50%
• Survivors: 50-70% have permanent neurological deficits
• Complete recovery: 20-30% [43,56]

Morbidity

Diabetes Insipidus:

• Acute: Dehydration, hypernatremia, AKI if untreated
• Chronic: Requires lifelong DDAVP (quality of life impact); risk of water intoxication with overtreatment
• Return to function: Most patients with transient DI fully recover

SIADH:

• Acute symptomatic hyponatremia: Falls, confusion, cognitive impairment
• Chronic hyponatremia: Even mild chronic hyponatremia associated with gait instability, falls, osteoporosis, fractures
• Post-treatment: ODS survivors may have permanent dysarthria, dysphagia, quadriparesis

Prognostic Factors

Good Prognostic Factors:

For DI:

• Transient post-operative DI (70-80% resolve)
• Intact thirst mechanism and access to water
• Prompt diagnosis and treatment
• Stalk intact on MRI (suggests transient DI)

For SIADH/Hyponatremia:

• Chronic, gradual onset (time for brain adaptation)
• Mild hyponatremia (greater than 125 mmol/L)
• Rapid diagnosis and appropriate management
• Treatable underlying cause (e.g., medication can be stopped)

Poor Prognostic Factors:

For DI:

• Associated with brain death
• Complete destruction of hypothalamic nuclei
• Delayed treatment with severe hypernatremia (greater than 170 mmol/L)
• Underlying malignancy

For SIADH/Hyponatremia:

• Acute severe hyponatremia (less than 120 mmol/L in less than 48 hours)
• Symptomatic with seizures or coma
• Overcorrection leading to ODS
• Underlying malignancy (especially SCLC with ectopic ADH)
• Chronic alcoholism (high ODS risk)

Indigenous Health Outcomes

Disparities:

• Aboriginal and Torres Strait Islander peoples have higher rates of chronic kidney disease affecting sodium handling
• Less frequent monitoring in remote areas
• Delayed access to specialist endocrinology
• Challenges with chronic DDAVP management (storage, compliance, education)
• Higher rates of alcohol-related conditions increasing ODS risk

Mitigation Strategies:

• Involve Aboriginal Health Workers in education and management planning
• Utilize telehealth for specialist consultation
• Ensure adequate DDAVP supply and storage in remote communities
• Culturally appropriate education materials
• Family-centered care model

---

SAQ Practice

SAQ 1: Post-TBI Diabetes Insipidus

Time Allocation: 10 minutes
Total Marks: 20

Stem:

A 35-year-old male was admitted to ICU following a severe motor vehicle accident. He sustained a traumatic brain injury with GCS 6 at scene. CT brain showed diffuse axonal injury with small contusions in the hypothalamic region. He has been intubated and sedated on propofol and fentanyl infusions.

On Day 2, the nursing staff reports urine output of 500 mL/hr for the last 4 hours. Observations: HR 115, BP 90/55, temperature 37.2C, CVP 2 mmHg.

Investigations:

• Serum sodium: 158 mmol/L
• Serum osmolality: 320 mOsm/kg
• Urine osmolality: 85 mOsm/kg
• Urine specific gravity: 1.002
• Creatinine: 110 umol/L (baseline 80)

---

Question 1.1 (8 marks)

Outline the pathophysiology of diabetes insipidus in this patient and explain the diagnostic criteria that confirm your diagnosis.

Question 1.2 (6 marks)

Describe your immediate management priorities for the next 2 hours.

Question 1.3 (6 marks)

The patient continues to produce large volumes of urine despite DDAVP. Discuss possible reasons and your approach to further management.

---

Model Answer

Question 1.1 (8 marks)

Pathophysiology (4 marks):

Traumatic brain injury has caused damage to the hypothalamic-pituitary axis, specifically the hypothalamic nuclei (supraoptic and paraventricular nuclei) that synthesize ADH, or the hypothalamic-hypophyseal tract that transports ADH to the posterior pituitary.

• The hypothalamic contusions visualized on CT are consistent with direct trauma to ADH-producing neurons (1 mark)
• Loss of ADH production leads to failure to insert aquaporin-2 channels in the collecting duct principal cells (1 mark)
• Without AQP2, the collecting duct remains impermeable to water, resulting in excretion of large volumes of dilute urine (1 mark)
• The incidence of DI in severe TBI is 20-30%, correlating with injury severity and hypothalamic involvement (1 mark)

Diagnostic Criteria (4 marks):

This patient meets criteria for central diabetes insipidus:

The combination of polyuria with dilute urine (osmolality less than 300 mOsm/kg) in the setting of hypernatremia and hyperosmolality confirms DI. The clinical context (TBI with hypothalamic injury) suggests central rather than nephrogenic DI.

---

Question 1.2 (6 marks)

Immediate Management Priorities (2 hours):

1. Hemodynamic Resuscitation (2 marks):

• Administer 500-1000 mL 0.9% normal saline bolus to restore intravascular volume
• Insert arterial line for continuous BP monitoring
• Target MAP greater than 65 mmHg; initiate noradrenaline if hypotension persists after fluid bolus
• Insert central venous catheter if not already present

2. DDAVP Administration (2 marks):

• Give desmopressin 2 mcg IV immediately
• This is the definitive treatment for central DI
• Expect urine output to decrease within 30-60 minutes
• Plan to repeat every 8-12 hours or when urine output rises greater than 200 mL/hr

3. Free Water Replacement (2 marks):

• Calculate free water deficit: TBW x [(158/140) - 1]
  • TBW = 0.6 x 80 kg (estimated) = 48 L
  • Deficit = 48 x 0.129 = 6.2 L
• Once BP stable with 0.9% saline, switch to 0.45% saline or 5% dextrose
• Target sodium correction less than 10 mmol/L in first 24 hours (less than 0.5 mmol/L per hour)
• Replace ongoing urine losses with 0.45% saline or D5W until DDAVP effective
• Monitor serum sodium every 4 hours

---

Question 1.3 (6 marks)

Reasons for Persistent Polyuria Despite DDAVP (4 marks):

1. Nephrogenic component (2 marks):

   • Concurrent hypokalemia (check potassium; replace if low)
   • Hypercalcemia (check ionized calcium)
   • Medication effect (review medications for nephrotoxins)
   • Mixed central and nephrogenic DI can occur in TBI

2. Inadequate DDAVP dosing or administration issues (1 mark):

   • Dose may be insufficient; can increase to 4 mcg IV
   • Administration timing (ensure regular dosing)
   • Verify IV access is patent

3. Osmotic diuresis (0.5 marks):

   • Check glucose (hyperglycemia)
   • Check urea (elevated urea load)
   • Consider mannitol if recently administered for ICP

4. Severe axonal damage (0.5 marks):

   • If greater than 80-90% of ADH-producing neurons damaged, may require higher doses
   • Consider if progressing toward brain death

Further Management Approach (2 marks):

1. Check and correct electrolytes:

   • Potassium: Replace to greater than 4.0 mmol/L (hypokalemia impairs concentrating ability)
   • Magnesium: Replace to greater than 0.8 mmol/L

2. Increase DDAVP dose: Trial 4 mcg IV; monitor response

3. If no response to higher DDAVP:

   • Confirms nephrogenic component
   • Consider thiazide diuretic (paradoxically reduces urine output)
   • Consider vasopressin infusion 0.01-0.04 units/min (provides V1 and V2 effects)

4. Re-evaluate neurological status:

   • Persistent massive DI unresponsive to treatment may indicate brainstem involvement
   • Consider formal brain death assessment if other signs present
   • Discuss prognosis with family

---

Common Mistakes:

• Not calculating free water deficit
• Using only 0.9% saline (provides no free water)
• Failing to consider nephrogenic component (always check electrolytes)
• Over-rapid sodium correction
• Not recognizing DI as potential indicator of severe brain injury/brain death

---

SAQ 2: SIADH Workup and Management

Time Allocation: 10 minutes
Total Marks: 20

Stem:

A 62-year-old female was admitted to ICU from the respiratory ward. She has a history of small cell lung cancer diagnosed 3 months ago and is currently undergoing chemotherapy. She was admitted with increasing confusion over the past 48 hours.

Observations: HR 88, BP 125/78, RR 18, SpO2 97% on room air, T 36.8C

Examination: GCS 13 (E3V4M6), euvolemic (normal JVP, no edema, normal skin turgor), otherwise unremarkable

Investigations:

• Serum sodium: 119 mmol/L
• Serum osmolality: 248 mOsm/kg
• Urine osmolality: 520 mOsm/kg
• Urine sodium: 55 mmol/L
• Potassium: 3.8 mmol/L
• Creatinine: 65 umol/L
• Glucose: 5.8 mmol/L
• TSH: 2.1 mU/L (normal)
• Cortisol (9am): 450 nmol/L (normal)

---

Question 2.1 (8 marks)

Discuss the diagnostic criteria for SIADH and explain how this patient fulfills them. What is the likely cause of SIADH in this case?

Question 2.2 (6 marks)

Outline your management plan for this patient, including the rate of sodium correction and potential risks.

Question 2.3 (6 marks)

After 24 hours, the serum sodium has risen from 119 to 132 mmol/L. What complication should you be concerned about, and how would you manage this?

---

Model Answer

Question 2.1 (8 marks)

Bartter-Schwartz Diagnostic Criteria for SIADH (6 marks):

This patient fulfills all six criteria for SIADH.

Likely Cause (2 marks):

Small cell lung cancer (SCLC) is the most common malignancy associated with SIADH (1 mark):

• SCLC produces ectopic ADH (arginine vasopressin) in 10-15% of cases
• This is a paraneoplastic syndrome (Type A SIADH - erratic, uncontrolled secretion)
• Other contributors may include chemotherapy drugs and pain/nausea (non-osmotic ADH stimuli) (1 mark)

---

Question 2.2 (6 marks)

Management Plan (4 marks):

Immediate Management (2 marks):

This patient has moderate-severe symptomatic hyponatremia (Na 119, GCS 13):

1. Hypertonic saline: 100 mL 3% saline IV over 10 minutes

   • This will raise sodium by approximately 2 mmol/L
   • Reassess symptoms; may repeat x2 if persistent severe symptoms (target 4-6 mmol/L rise in first 2 hours)

2. Frequent monitoring: Check serum sodium every 2 hours initially

Ongoing Management (2 marks):

1. Fluid restriction: Less than 1000 mL/day once acute symptoms controlled
2. Salt tablets: 1-3 g sodium chloride orally TDS
3. Consider tolvaptan: If fluid restriction fails; start 15 mg daily with close sodium monitoring
4. Treat underlying cause: Continue chemotherapy as per oncology; SIADH may improve with tumor response

Rate of Sodium Correction (2 marks):

Critical Targets:

• Maximum correction: 8-10 mmol/L in first 24 hours
• In this patient with chronic hyponatremia (greater than 48 hours): Aim for less than 8 mmol/L/24h
• First 1-2 hours: 4-6 mmol/L to control symptoms (target Na 123-125 mmol/L)
• Then slow to 0.5-1 mmol/L/hour thereafter

Risks:

• Overcorrection causing osmotic demyelination syndrome (ODS)
• This patient is at moderate risk (chronic hyponatremia) - requires strict monitoring

---

Question 2.3 (6 marks)

Concern: Osmotic Demyelination Syndrome (ODS) (2 marks):

This patient has been overcorrected:

• Rise of 13 mmol/L in 24 hours (119 → 132)
• This exceeds the recommended maximum of 8-10 mmol/L/24h
• Significantly increases risk of ODS

ODS Presentation (2 marks):

• May develop 2-6 days after overcorrection
• Symptoms: Dysarthria, dysphagia, quadriparesis, altered consciousness, locked-in syndrome
• Risk factors in this patient: Chronic hyponatremia (greater than 48 hours duration)
• Initial MRI may be normal; changes develop over 1-2 weeks

Management (2 marks):

Immediate Actions:

1. DDAVP Clamp Protocol:

   • Administer DDAVP 2 mcg IV immediately
   • Begin 5% dextrose (D5W) infusion at 3 mL/kg/hr
   • Target: Lower sodium back to approximately 125-127 mmol/L
   • Re-inducing mild hyponatremia may be protective

2. Monitoring:

   • Check sodium every 2 hours
   • Close neurological monitoring for ODS symptoms
   • Repeat MRI brain in 7-10 days if symptoms develop

3. Continue DDAVP:

   • Give 2 mcg IV every 6-8 hours for 24-48 hours
   • This maintains controlled "iatrogenic SIADH" preventing further sodium rise

4. Documentation and Communication:

   • Document overcorrection and remedial actions
   • Inform patient/family of risk
   • Consider ICU level care for close monitoring

---

Common Mistakes:

• Not recognizing severity requiring 3% saline
• Failure to limit correction rate
• Using tolvaptan for acute severe symptomatic hyponatremia (3% saline is first-line)
• Not implementing DDAVP clamp for overcorrection
• Missing the opportunity to prevent ODS with early intervention

---

Viva Scenarios

Viva Scenario 1: Differentiating Hyponatremia Causes

Stem: "A 55-year-old male is Day 5 post-clipping of a ruptured anterior communicating artery aneurysm. He has developed hyponatremia (Na+ 126 mmol/L). The neurosurgical team asks you to differentiate SIADH from cerebral salt wasting."

Duration: 12 minutes (2 min reading + 10 min discussion)

---

Opening Question: "What are the key clinical and laboratory features that distinguish SIADH from cerebral salt wasting?"

Model Answer:

"SIADH and cerebral salt wasting (CSW) are both causes of hyponatremia after neurosurgical procedures, particularly subarachnoid hemorrhage. The crucial distinction is volume status:

Clinical Assessment:

Laboratory Features:

Both conditions have elevated urine sodium and concentrated urine. The sodium balance differentiates them:

In SAH patients, I would specifically look for:

• Daily trends in weight, CVP, and fluid balance
• Response to fluid challenge (CSW improves, SIADH may worsen)
• This patient is Day 5 post-SAH, which is peak incidence for both conditions"

---

Follow-up Question 1: "The patient is found to be hypovolemic. How would you manage cerebral salt wasting?"

Model Answer:

"Confirming hypovolemia changes the management entirely. Unlike SIADH, fluid restriction would be harmful in CSW:

Immediate Management:

1. Volume Replacement:

   • 0.9% normal saline bolus 500-1000 mL
   • Target euvolemia (CVP 6-10 cmH2O)
   • May need 3-4 L daily in severe CSW

2. Sodium Correction:

   • If symptomatic or Na less than 120 mmol/L: 3% hypertonic saline
   • Calculate sodium deficit and correct gradually
   • Rate: Less than 8-10 mmol/L/24h (same as SIADH - avoid ODS)

3. Maintenance:

   • 0.9% saline infusion with potassium replacement
   • Salt tablets 1-3 g orally TDS if able to take orally

4. Mineralocorticoid Therapy:

   • Fludrocortisone 0.1-0.2 mg daily
   • Enhances sodium retention in the distal nephron
   • Monitor for hypokalemia and fluid overload

5. Monitoring:

   • Serum sodium every 4-6 hours
   • Strict fluid balance
   • Daily weights
   • Watch for overcorrection

The key difference is that we are replacing losses in CSW, not restricting fluids as in SIADH."

---

Follow-up Question 2: "What is the pathophysiology of cerebral salt wasting?"

Model Answer:

"The exact mechanism of CSW remains debated, but the leading hypothesis involves natriuretic peptide release:

Proposed Mechanisms:

1. Brain Natriuretic Peptide (BNP) Release:

   • Neuronal injury causes BNP release from brain tissue
   • BNP promotes natriuresis and water excretion
   • May also involve atrial natriuretic peptide (ANP)

2. Decreased Sympathetic Nervous System Activity:

   • CNS injury may reduce sympathetic outflow
   • Decreased renal sympathetic tone promotes sodium excretion
   • Reduced proximal tubular sodium reabsorption

3. Reduced Aldosterone Sensitivity:

   • Impaired aldosterone action despite normal levels
   • Contributes to sodium wasting

Clinical Context in SAH:

• More common in anterior circulation aneurysms
• Peak incidence days 5-10 (overlaps with vasospasm risk period)
• Volume depletion may worsen vasospasm (additional reason for aggressive treatment)
• Some experts believe CSW is overdiagnosed and many cases are actually SIADH

Distinguishing from SIADH at Molecular Level:

In SIADH, ADH causes water retention via V2 receptor/aquaporin-2 pathway, leading to dilutional hyponatremia. In CSW, there is true sodium loss with secondary volume contraction."

---

Follow-up Question 3: "What are the implications for vasospasm prevention in this SAH patient?"

Model Answer:

"This is a critical clinical concern. CSW-induced hypovolemia can worsen cerebral vasospasm outcomes:

Triple-H Therapy Considerations:

Traditional 'Triple-H' therapy (Hypertension, Hypervolemia, Hemodilution) for vasospasm has evolved, but euvolemia remains essential:

1. Hypovolemia Risk:

   • Reduced cerebral perfusion pressure
   • Increased blood viscosity (hemoconcentration)
   • May precipitate delayed cerebral ischemia (DCI)

2. Management Priorities:

   • Maintain euvolemia (target CVP 8-12 cmH2O or equivalent)
   • Avoid hypotension (MAP target often greater than 90 mmHg in vasospasm)
   • Induced hypertension if symptomatic vasospasm develops

3. Current Evidence:

   • CONSCIOUS-1/2 trials and others have moved away from prophylactic hypervolemia
   • Focus is on euvolemia and treating symptomatic vasospasm
   • Nimodipine remains standard prophylaxis

4. Monitoring:

   • Daily transcranial Doppler for vasospasm detection
   • CT perfusion if available
   • Close neurological monitoring

In this patient, correcting hypovolemia is doubly important: it treats the hyponatremia AND optimizes cerebral perfusion. I would discuss with neurosurgery and consider early neurovascular team input."

---

Viva Scenario 2: DDAVP Dosing and Monitoring

Stem: "A 40-year-old female has developed central diabetes insipidus following transsphenoidal resection of a craniopharyngioma. She is on Day 1 post-operatively with urine output of 350 mL/hr for the last 3 hours. Serum sodium is 152 mmol/L."

Duration: 12 minutes (2 min reading + 10 min discussion)

---

Opening Question: "How would you initiate and monitor DDAVP therapy in this patient?"

Model Answer:

"This patient has confirmed central DI based on post-pituitary surgery with polyuria and hypernatremia. DDAVP (desmopressin) is the treatment of choice.

Initial DDAVP Administration:

1. Route and Dose:

   • IV route preferred in ICU: Give DDAVP 2 mcg IV initially
   • Onset within 15-30 minutes; duration 8-12 hours
   • Alternative: 1-4 mcg SC if IV access limited

2. Expected Response:

   • Urine output should decrease within 1-2 hours
   • Target urine output less than 200 mL/hr
   • Urine osmolality should increase (greater than 300 mOsm/kg)

Monitoring Protocol:

Ongoing Dosing Strategy:

There are two approaches:

1. Fixed Dosing: DDAVP 1-2 mcg IV every 8-12 hours

   • Simple, predictable
   • Risk of hyponatremia if free water intake not controlled

2. Breakthrough Dosing (preferred in early post-op):

   • Give DDAVP only when urine output rises significantly
   • Allow brief periods of polyuria to prevent water retention
   • Reduces risk of hyponatremia from overcorrection
   • More physiological approach

Cautions:

• Always provide free water replacement separately, but be cautious of giving large volumes while DDAVP is active
• Watch for Phase 2 of triple-phase response (SIADH phase) - may need to hold DDAVP if sodium falls or urine output decreases
• Document time of administration and duration of effect to guide future dosing"

---

Follow-up Question 1: "What formulations of DDAVP are available and how would you transition this patient to outpatient therapy?"

Model Answer:

"DDAVP is available in multiple formulations with different bioavailability and dosing:

Available Formulations:

Transition Protocol:

1. When to Transition:

   • Patient stable on IV DDAVP
   • Oral intake established
   • Predictable DDAVP requirements over 24-48 hours

2. Conversion:

   • Rule of thumb: 2 mcg IV ≈ 10-20 mcg intranasal ≈ 100-200 mcg oral
   • Start at lower end and titrate to response

3. Outpatient Education:

   • Recognition of DI symptoms (thirst, polyuria)
   • Importance of not drinking excessively after dose (hyponatremia risk)
   • When to seek medical attention
   • Medication storage (intranasal requires refrigeration)

4. Follow-up:

   • Endocrinology referral
   • Sodium monitoring initially weekly, then monthly
   • Assess for other pituitary hormone deficiencies

Special Consideration for Indigenous/Remote Patients:

• Oral formulation preferred (no refrigeration needed, easier storage)
• Ensure adequate supply before discharge
• Telehealth follow-up arrangements
• Written instructions and education for family/carers"

---

Follow-up Question 2: "On Day 4, the patient develops oliguria (20 mL/hr) and sodium has dropped to 130 mmol/L. You have not given DDAVP for 18 hours. What is happening?"

Model Answer:

"This clinical picture is consistent with Phase 2 of the triple-phase response:

Triple-Phase Response:

This patient has transitioned from Phase 1 (DI) to Phase 2 (SIADH-like picture):

Pathophysiology:

• Dying neurohypophyseal neurons release stored ADH in an uncontrolled manner
• Results in inappropriate water retention despite low serum osmolality
• Patient appears to have SIADH but it is transient

Management:

1. Hold DDAVP: Should already be held (has been for 18 hours)
2. Fluid restriction: Less than 1000 mL/day
3. Monitor sodium: Every 4-6 hours
4. Avoid overcorrection: If sodium was 152 and now 130, this is a 22 mmol/L change
   • However, this occurred over 4 days, which is approximately 5-6 mmol/L/day - acceptable

Anticipating Phase 3:

• Not all patients complete all three phases
• Some recover normal function, especially if stalk intact
• Monitor for return of polyuria (Phase 3)
• If sodium begins rising and urine output increases after Day 7, restart DDAVP

Communication:

• Inform neurosurgical team of phase transition
• Update family on prognosis (if permanent DI develops, will need lifelong DDAVP)
• Document clearly in medical record"

---

Follow-up Question 3: "What complications should you warn the patient about regarding long-term DDAVP use?"

Model Answer:

"Long-term DDAVP therapy is generally safe but has several important considerations:

Hyponatremia (Water Intoxication):

This is the most important complication:

• Occurs if patient drinks excessively while DDAVP is active
• Particularly risky with fixed dosing schedules
• Symptoms: Confusion, nausea, seizures
• Prevention: Educate about limiting fluid intake, especially in first few hours after dose
• Some patients use 'escape' day (skip dose weekly, allowing diuresis)

Other Considerations:

1. Headache: Common side effect (10-20%); usually mild

2. Flushing/Facial Redness: Vasodilatory effect; generally tolerable

3. Nausea: Can occur with oral formulation

4. Hypertensive Episodes: Rare; avoid in uncontrolled hypertension

5. Nasal Congestion (Intranasal): May affect absorption; switch formulations during URTIs

6. Thrombotic Risk: Theoretical concern (DDAVP releases vWF); avoid in patients with cardiovascular disease if possible

Monitoring Recommendations:

• Serum sodium: Weekly initially, then monthly once stable, then 3-6 monthly
• Educate about symptoms of hyponatremia
• Weight monitoring (sudden weight gain suggests water retention)

Special Populations:

• Elderly: Higher risk of hyponatremia; lower doses
• Cardiac patients: Volume overload risk; cautious dosing
• Pediatric: Weight-based dosing; education of parents

Quality of Life:

• Generally good with proper management
• May need dose adjustment for exercise (increased sweating reduces need)
• Travel considerations (time zones, hot climates)
• Pregnancy: Generally safe but needs specialist input

I would ensure this patient has endocrinology follow-up and written information about her condition."